ReviewInfectious disease clinics of North America2022
Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children.
Review in Infectious disease clinics of North America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Clinical Outcomes of Pediatric Cancer Patients with COVID-19: A Cross-Sectional Study.International journal of hematology-oncology and stem cell research · 2024Article
- Effect of the COVID-19 pandemic on the pediatric infectious disease landscape.European journal of pediatrics · 2024Review
- Spectrum of severity of multisystem inflammatory syndrome in children: an EHR-based cohort study from the RECOVER program.Scientific reports · 2023Article
- Acceptability and Feasibility of Saliva-delivered PCR Coronavirus 2019 Tests for Young Children.Pediatrics · 2023Article
- Anti-SARS-CoV-2 antibodies in breast milk during lactation after infection or vaccination: A cohort study.Journal of reproductive immunology · 2022Article
- Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years.JAMA network open · 2022Article
- Myocardial Infarction in Children after COVID-19 and Risk Factors for Thrombosis.Diagnostics (Basel, Switzerland) · 2022Article
- Editorial: COVID-19 and hyper inflammation syndrome: Different presentation and management.Frontiers in pediatrics · 2022Article
- Inflammatory Markers in Pediatric Bacterial Sepsis vs. SARS-CoV-2 Infection: A Retrospective Study.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in children generally have milder presentations, but severe disease can occur in all ages. MIS-C and persistent post-acute COVID-19 symptoms can be experienced by children with previous infection and emphasize the need for infection prevention. Optimal treatment for COVID-19 is not known, and clinical trials should include children to guide therapy. Vaccines are the best tool at preventing infection and severe outcomes of COVID-19. Children suffered disproportionately during the pandemic not only from SARS-CoV-2 infection but because of disruptions to daily life, access to primary care, and worsening income inequalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.